Michael Cottler is a partner in the firm's Litigation Department, where he focuses his practice on intellectual property, with a concentration on patent issues in the areas of biotechnology and pharmaceuticals. He has represented pharmaceutical companies in complex litigations, particularly Hatch-Waxman/ANDA cases, relating to various types of chemical agents and pharmaceutical products across a spectrum of medical indications. He joined Goodwin in 2006.

Experience

Erfahrung

工作经历

Mr. Cottler advises clients in the pharmaceutical and biotechnology industries on a number of intellectual property matters. His experience includes patent litigation, client counseling (including invalidity and clearance opinions), and due diligence. Mr. Cottler has extensive experience handling all aspects of patent litigation, including overseeing fact and expert discovery, examining witnesses at trial, preparing pretrial motions and briefs, and arguing in Court relating to discovery disputes, claim construction, Daubert motions, and motions in limine. The following are a representation of Mr. Cottler’s matters:

  • Prometheus Laboratories Inc. v. Roxane Laboratories, Inc., et al., No. 2:11-cv-01241 (D.N.J.)

Mr. Cottler is a member of the team representing Roxane and Cipla in a patent infringement litigation filed by Prometheus under the Hatch-Waxman Act in response to Roxane’s filing of an abbreviated new drug application seeking approval to market a generic version of Prometheus’s IBS treatment drug, LOTRONEX® (alosetron hydrochloride). After a bench trial, the District Court found Prometheus’s patent invalid, enabling Roxane to launch the first generic version of LOTRONEX®. Judgement was affirmed on appeal.

  • Cadence Pharmaceuticals, Inc., et al. v. Fresenius Kabi USA, LLC, No. 13-cv-00139 (S.D. Cal.)

Mr. Cottler was a member of the team representing Fresenius in a patent infringement litigation filed by Cadence under the Hatch-Waxman Act in response to Fresenius’s filing of a 505(b)(2) application seeking approval to market a generic version of Cadence’s pain medication, OFIRMEV® (acetaminophen). The case settled favorably before trial.

  • Teva Pharmaceuticals USA, Inc. v. Amgen, Inc., No. 09-cv-5675 (E.D. Pa.)

Mr. Cottler was a member of the team representing Teva  in a declaratory judgment action filed by Teva regarding its Biologics License Application seeking approval to market its recombinant G-CSF product, a version of Amgen Inc.’s drug, NEUPOGEN®. The case settled favorably before trial, enabling Teva to launch, prior to patent expiration, the first G-CSF product in the U.S. market in over ten years.

  • Novartis Pharmaceuticals Corporation, et al. v. Roxane Laboratories, Inc., No. 1:14-cv-01508 (D. Del.)

Mr. Cottler is a member of the team representing Roxane in an ongoing patent infringement litigation filed by Novartis under the Hatch-Waxman Act in response to Roxane’s filing of an abbreviated new drug application seeking approval to market a generic version of Novartis’s anti-cancer product, AFINITOR® (everolimus).

  • Tris Pharma, Inc. v. Actavis Laboratories FL, Inc.,  No. 1:14-cv-01309 (D. Del.)

Mr. Cottler is a member of the team representing Actavis in an ongoing patent infringement litigation filed by Tris under the Hatch-Waxman Act in response to Actavis’s filing of an abbreviated new drug application seeking approval to market a generic version of Pfizer’s ADHD product, QUILLIVANT® (methlyphenidate).

  • Genzyme Corporation, et al. v. Teva Pharmaceuticals USA, Inc., et al., No. 1:13-cv-01506 (D. Del.)

Mr. Cottler is a member of the team representing Teva in an ongoing patent infringement litigation filed by Genzyme under the Hatch-Waxman Act in response to Teva’s filing of an abbreviated new drug application seeking approval to market a generic version of Genzyme’s stem cell mobilizing agent, MOZOBIL® (plerixafor). The case is now on appeal.

Professional Activities

Mr. Cottler is a member of the American Bar Association, the New York Bar Association and the New York City Bar Association (Patents Committee, 2009-2012 (Secretary); 2014-present).

Recognition

While attending law school, Mr. Cottler was a senior editor of the Albany Law Review. Mr. Cottler was also a Sponsler Fellow, an Honors Teaching Fellowship program in which second-year students in the top 10 percent of their class are assigned to a section of first-semester Federal Civil Procedure as a teaching fellow.

In The News

In den Nachrichten

在新闻中

Credentials

Anmeldeinformationen

专业资格

Education

J.D., 2006
Albany Law School

(magna cum laude)

B.S., Biological Sciences concentration in Neuroscience, 2002
Cornell University

Admissions

Bar

New York
Connecticut

Courts

U.S. District Court for the Southern District of New York
U.S. District Court for the Eastern District of New York
U.S. Court of Appeals for the Federal Circuit
Get In Touch
In Kontakt kommen
Get In Touch
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
Suche Andere Rechtsanwälte
搜寻其他律师